Transdermal delivery of estrogen therapy available by prescription “seems not to alter” the risk of venous thromboembolism, or blood clotting, in postmenopausal patients when compared to oral delivery, a new study suggests.
Transdermal delivery of estrogen therapy available by prescription “seems not to alter” the risk of venous thromboembolism, or blood clotting, in postmenopausal patients when compared to oral delivery, a new study suggests.